Phase II trial of axalimogene filolisbac (ADXS-HPV) in combination with epacadostat (INCB-24360) in patients with HPV-associated cervical cancer

Trial Profile

Phase II trial of axalimogene filolisbac (ADXS-HPV) in combination with epacadostat (INCB-24360) in patients with HPV-associated cervical cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Axalimogene filolisbac (Primary) ; Epacadostat (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Sponsors Advaxis; Incyte Corporation
  • Most Recent Events

    • 08 Jan 2016 According to an Advaxis Immunotherapies media release, this trial is expected to commence in the first half of 2016.
    • 01 Dec 2015 According to the Advaxis Inc. media release, the US FDA has granted orphan drug designation for axalimogene filolisbac in the treatment of cervical cancer.
    • 01 Jun 2015 According to an Advaxis media release, US FDA has approved the Investigational New Drug (IND) application for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top